Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06983964
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Autoimmune Disease
Interventions
GENETIC:
CD19 CART
Sponsor
Beijing Boren Hospital